Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111 CHX-A DTPA trastuzumab

An indium I 111-labeled trastuzumab with potential use as an imaging agent. Indium In 111 CHX-A DTPA trastuzumab is chemically conjugated via a bifunctional metal chelator molecule, 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A DTPA), a backbone-substituted derivative of DTPA. This agent may allow radioimmunolocalization of HER2-positive cells. Trastuzumab, a recombinant humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2), may elicit an antibody-dependent cellular cytotoxicity (ADCC) against tumor cells that overexpress HER2.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

indium In 111 CHX-A DTPA trastuzumab

Search NCI's Drug Dictionary